Skip to content
naulon
Not checkedNot checked for notices yet.

The clinical experience of macitentan in pulmonary hypertension in Indian cohort: 12-months follow-up

Pankaj Jariwala, Kartik Jadhav, Saket Khetan and 1 more

Indian Heart Journal · 2021

doi:10.1016/j.ihj.2021.11.078 (opens in a new tab)

We email you when a new notice or a question about this paper appears.

Abstract

122.8 ± 10.6 mmHg and diastolic blood pressure (DBP) from 98.7 ± 11.2 to 77.0 ± 6.7 mmHg (all P < 0.001).The pulse rate decreased from 84.4 ± 10.6 to 67.9 ± 9.4 beats/min in comparison with before treatment (P < 0.001).The reductions were similar between sexes, age groups, and patients with and without co-morbidities, and were not dependent on prior or concomitant treatment with other antihypertensive drugs.Adverse events were reported in 1.31 % (treatment-emergent) and 0.35 % (drug-related) of patients; there were no dose differences for adverse events.The most frequent adverse events were dizziness (1.2 %) and headache (0.3 %); other adverse events were rare.The responder rate (DBP to <90 mmHg or a reduction of 10 mmHg) and the goal rate (combined SBP/DBP <130/80 mmHg) were 95.0 and 85.4 %, respectively.Conclusion: The safety, efficacy, and compliance of fimasartan were found to be excellent in a large patient population that included patients potentially at higher risk for adverse events.

Abstract licence: CC BY-NC-ND

Reads

Read by people on this page

None yet.

Checked or read by AI through naulon

None yet.

A person counts once a day per paper. We keep no cookie and no address: a reader is a hash that changes every day. Any month under five reads shows no number.

Are you an author?

Is this your paper?

Claim it to add your note and be paid when agents cite it. Free.